Phase I/II Study of LY2090314 and Chemotherapy in Metastatic Pancreatic Cancer Patients With Metastases Amenable to Biopsy

Trial Profile

Phase I/II Study of LY2090314 and Chemotherapy in Metastatic Pancreatic Cancer Patients With Metastases Amenable to Biopsy

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 29 Feb 2016

At a glance

  • Drugs LY 2090314 (Primary) ; Fluorouracil; Folinic acid; Gemcitabine; Oxaliplatin; Paclitaxel
  • Indications Pancreatic cancer
  • Focus Pharmacodynamics
  • Sponsors Eli Lilly
  • Most Recent Events

    • 25 Feb 2016 Status changed from active, no longer recruiting to discontinued, according to ClinicalTrials.gov record.
    • 25 Feb 2016 Status changed from active, no longer recruiting to discontinued, according to ClinicalTrials.gov record.
    • 07 Oct 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top